Abstract: A crystalline Boehmite product and a method of forming said product is provided in which the crystalline Boehmite exhibits an average particle size (d50) that is less than 7,000 nanometers. This method comprises preparing an aqueous slurry by mixing together water, large aluminum oxide precursors, a highly dispersible Boehmite grade, and optionally, an organic dispersing agent; adjusting the pH of the slurry; heating the slurry for a predetermined duration of time; collecting the slurry to form a wet cake; and drying the wet cake to obtain the crystalline Boehmite product. The crystalline Boehmite product may be mixed with a plastic resin to form a flame retardant plastic mixture, which can be subjected to a conventional plastic processing method to form a flame retardant composite.

Abstract: The present disclosure generally provides novel STT-type zeolite materials called PIDC-120501, PIDC-120502, and PIDC-120805/120806 or PIDC-type zeolites and a method of making these zeolites. The present disclosure also provides for the use of these zeolite materials as a catalyst and a method of preparing said catalyst. The PIDC-type zeolites or STT-type zeolite materials may be used as a catalyst, such as in Selective Catalytic Reduction (SCR) applications.

Abstract: The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.

Abstract: The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.

Abstract: The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.

Abstract: Mesoporous, zirconium-based mixed oxides and a method of making the same comprises: injecting a polyvalent metal-containing solution into an electrolyte solution to form a mother liquor; forming a precipitate; aging the precipitate in the mother liquor to form the mixed oxides; washing the mixed oxides with an aqueous medium; drying and collecting the mixed oxides. The pH of the electrolyte solution exceeds the isoelectric point for zirconium-based mixed oxides. The mixed oxides exhibit a single particle size distribution, improved Ce02 reducibility in the presence of Rhodium, a decrease in surface area after calcination (800-1 100° C.) that is not more than 55%, and a tetragonal/cubic structure after calcination. After calcination at 1 100° C. for 10 hours in air, the mixed oxides exhibit a surface area >25 m2/g, a pore volume >0.20 cm3/g, an average pore size >30 nm, and an average crystallite size between 8-15 nm.

Abstract: A catalyst support material (D-CZMLA) with oxygen storage capacity corresponds to the formula vD:x(Ce1-wZrwO2):yM:zL:(1-v-x-y-z)Al2O3, wherein w is a molar ratio between 0.1-0.8 and v, x, y, and z are weight ratios, such that v is between 0.005-0.15, x is between 0.05-0.80, and y and z are between 0.001-0.10. M is an interactive promoter for oxygen storage, L is a stabilizer (L) for the Al2O3 support; and D is an oxidizing dopant. The catalyst support material can be incorporated into a wash coat that combines platinum group metals (PGM), an adhesive, and a mixture of (?)RE-Ce—ZrO2+(?)CZMLA+(1????)RE-Al2O3, wherein RE-Ce—ZrO2 is a rare earth element stabilized ceria zirconia having a weight ratio (?) between 0-0.7; CZMLA is the doped catalyst support material having a weight ratio (?) between 0.2-1, such that (?+?)?1; and RE-Al2O3 is rare earth element stabilized alumina having a weight ratio equal to (1????).

Abstract: A crystalline Boehmite product and a method of forming said product is provided in which the crystalline Boehmite exhibits an average particle size (d50) that is less than 7,000 nanometers. This method comprises preparing an aqueous slurry by mixing together water, large aluminum oxide precursors, a highly dispersible Boehmite grade, and optionally, an organic dispersing agent; adjusting the pH of the slurry; heating the slurry for a predetermined duration of time; collecting the slurry to form a wet cake; and drying the wet cake to obtain the crystalline Boehmite product. The crystalline Boehmite product may be mixed with a plastic resin to form a flame retardant plastic mixture, which can be subjected to a conventional plastic processing method to form a flame retardant composite.

Abstract: The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.

Abstract: A catalyst support material (D-CZMLA) with oxygen storage capacity corresponds to the formula vD:x(Ce1-wZrwO2):yM:zL:(1?v?x?y?z)Al2O3, wherein w is a molar ratio between 0.1-0.8 and v, x, y, and z are weight ratios, such that v is between 0.005-0.15, x is between 0.05-0.80, and y and z are between 0.001-0.10. M is an interactive promoter for oxygen storage, L is a stabilizer (L) for the Al2O3 support; and D is an oxidizing dopant. The catalyst support material can be incorporated into a wash coat that combines platinum group metals (PGM), an adhesive, and a mixture of (?)RE-Ce—ZrO2+(?)CZMLA+(1????)RE-Al2O3, wherein RE-Ce—ZrO2 is a rare earth element stabilized ceria zirconia having a weight ratio (?) between 0-0.7; CZMLA is the doped catalyst support material having a weight ratio (?) between 0.2-1, such that (?+?)?1; and RE-Al2O3 is rare earth element stabilized alumina having a weight ratio equal to (1????).

Abstract: A surgical method according to an exemplary aspect of the present disclosure includes, among other things, drying an osteochondral defect using a suction swab. The drying step includes suctioning moisture from the osteochondral defect through the suction swab or communicating a gas to the osteochondral defect through the suction swab.

Abstract: The present disclosure generally provides novel STT-type zeolite materials called PIDC-120501, PIDC-120502, and PIDC-120805/120806 or PIDC-type zeolites and a method of making these zeolites. The present disclosure also provides for the use of these zeolite materials as a catalyst and a method of preparing said catalyst. The PIDC-type zeolites or STT-type zeolite materials may be used as a catalyst, such as in Selective Catalytic Reduction (SCR) applications.

Abstract: A platform for a loyalty program provides an interface allowing a consumer to create a benefit tailored for his/her needs. In one embodiment, a consumer accesses the platform via a web-based interface, and selects benefit/reward parameters including but not limited to the nature of the event triggering award of the benefit, the source (i.e. retailer) of the benefit, the nature of the benefit (i.e., discount based upon purchase price or accumulated loyalty points), and/or the events allowing accrual of loyalty points. The interface communicates the inputted parameter to an engine of the loyalty program. The platform would then check the inputted parameter against any constraints, such as parameters of an existing loyalty program in which the consumer is already enrolled.

Abstract: A platform for a loyalty program provides an interface allowing a consumer to create a benefit tailored for his/her needs. In one embodiment, a consumer accesses the platform via a web-based interface, and selects benefit/reward parameters including but not limited to the nature of the event triggering award of the benefit, the source (i.e. retailer) of the benefit, the nature of the benefit (i.e., discount based upon purchase price or accumulated loyalty points), and/or the events allowing accrual of loyalty points. The interface communicates the inputted parameter to an engine of the loyalty program. The platform would then check the inputted parameter against any constraints, such as parameters of an existing loyalty program in which the consumer is already enrolled.

Abstract: A platform for a loyalty program provides an interface allowing a consumer to create a benefit tailored for his/her needs. In one embodiment, a consumer accesses the platform via a web-based interface, and selects benefit/reward parameters including but not limited to the nature of the event triggering award of the benefit, the source (i.e. retailer) of the benefit, the nature of the benefit (i.e., discount based upon purchase price or accumulated loyalty points), and/or the events allowing accrual of loyalty points. The interface communicates the inputted parameter to an engine of the loyalty program. The platform would then check the inputted parameter against any constraints, such as parameters of an existing loyalty program in which the consumer is already enrolled.

Abstract: Collaborative constituents collaborate to develop a loyalty program within a transaction processing system. Transmissions addressed to the collaborative constituents are formed and received from the collaborative constituents containing suggested parameters for the loyalty program. At least one remaining parameter for the loyalty program that a set of remaining collaborative constituents have agreed upon is determined. Another transmission addressed to each of the collaborative constituents in the set of remaining collaborative constituents is formed, the another transmission including the remaining parameters for the loyalty program.

Abstract: A suture needle construct and method for extracapsular ligament reconstruction in mammals. The joint is first is first explored, and the damaged ligament and meniscus are debrided. The joint capsule is closed and a tunnel is created at the appropriate location in the proximal tibia for tibial fixation. Subsequent to the formation of the tibial tunnel, a suture having a substantially curved needle at one end and a substantially straight needle at the other end is brought in the proximity of the joint. The suture is passed around the lateral fabella using the substantially curved needle, then deep to the patellar ligament using the substantially straight needle, and through the tibial tunnel using the straight needle. The needles are cut off, and the sutures are tensioned over repair site.

Abstract: A new optimization method for generating treatment plans for radiation oncology is described and claimed. This new method works for intensity modulated radiation therapy (IMRT), intensity modulated arc therapy (IMAT), and hybrid IMRT.

Abstract: An osteochondral centrifugation system for providing an osteochondral centrifuged core from a graft such as femoral condyle, for example. The centrifugation system may be used either in the operating room or, alternatively, at a tissue banking facility at the time of processing. The osteochondral centrifuged core is formed by (i) removing an osteochondral core from a graft; (ii) placing the osteochondral core in a centrifugation system to remove blood, lipids, or other potentially antigenic or contaminating materials, and to obtain a centrifuged core; and (iii) optionally, subjecting the centrifuged core to a material that reduces the chance of disease transmission and aids in the healing of the recipient site to which the centrifuged core is to be transferred.

Abstract: A method of producing blood serum containing prophylactically or therapeutically active proteins, including obtaining blood from a patient, incubating the blood at a suitable temperature to induce production of prophylactically or therapeutically active proteins, and removing the prophylactically or therapeutically active proteins from the blood.